Connect with us

Technology

Cyngn Reports 2024 Fourth Quarter and Year-End Financial Results

Published

on

 Recent Operating Highlights:

Cyngn received approximately $1.3M of new bookings for DriveMod vehicles from direct sales during Q4-2024Cyngn Signed Contract to Deploy DriveMod Tugger at a Major Consumer Packaged Goods CompanyCyngn Announced Multiple Deployments at Major Automotive Brands, including Coats.Cyngn Raised $33m in December to Scale Customer Deployments and Fuel Its GrowthCyngn Highlighted its Proprietary Computer Vision Advancements with NVIDIA Accelerated ComputingCyngn Hired Marty Petraitis, a veteran of Industrial Automation, as VP of Sales.Cyngn Successfully Completed Initial Deployment of Its DriveMod Tugger at a Major Defense ContractorCyngn Completed First Paid DriveMod Forklift Deployment at Customer FacilityCyngn’s Next-Generation 12,000-lb DriveMod Tugger Completed Production Builds at Motrec Facility

MENLO PARK, Calif., March 5, 2025 /PRNewswire/ — Cyngn Inc. (Nasdaq: CYN) today announced financial results for its fourth quarter and year, which ended December 31, 2024.

“We continued to gain commercial momentum with our autonomous DriveMod technology,” said Lior Tal, Cyngn CEO. “Building on the direct sales progress made earlier in the year—including our selection by John Deere to supply the DriveMod Tugger—we received over $1M in new bookings from direct sales in the fourth quarter and are actively expanding our focus on channel sales to accelerate adoption.

“We have also recently achieved a meaningful market expansion milestone with a contract signed for our DriveMod Tugger at a Consumer Packaged Goods company, an important progression to bringing our solutions to an even wider swath of industries. Additionally, we kicked off a production deployment of our vehicles at Coats, a major North American Automotive Service Equipment Manufacturer, which continues to emphasize our traction in the automotive manufacturing industry.”

Steve Bergmeyer, Continuous Improvement and Quality Manager at Coats, said “Cyngn’s self-driving tugger was the perfect solution to support our strategy of advancing automation and incorporating scalable technology seamlessly into our operations. With its high load capacity, we can concentrate on increasing our ability to manage heavier components and bulk orders, driving greater efficiency, reducing costs, and accelerating delivery timelines.”

Cyngn hired Marty Petraitis, an experienced veteran of the industrial automation industry, as VP of Sales to capitalize on its growing opportunities. The company is actively focusing on expanding into more Fleet Purchases, creating more scaled opportunities with onboarded customers. Cyngn is seeing validation of its solutions, especially through traction in heavy manufacturing industries like automotive.

The company’s momentum is highlighted by the additional recent deployments of the next-generation 12,000 lb. DriveMod Tugger at customer facilities and multiple new customer contracts and LOIs. The next-gen DriveMod Tugger boasts increased towing capacity and enhanced autonomous capabilities with a small form factor for its high towing capacity. Technological improvements have expanded possible use cases, broadened the environments where Cyngn’s autonomous vehicles deliver value, and ultimately created new sales opportunities.

Having ramped up the production of its DriveMod Tugger, Cyngn has also been able to shift to revenue-generating activities with its autonomous DriveMod Forklift solution. The first paid DriveMod Forklift deployment marked a key turning point in monetizing the valuable solution offered by an autonomous forklift.

The global forklift market is expected to double to $103.9 billion by 2031. The opportunity for autonomous forklifts is significant, and this milestone positions Cyngn for the critical next steps that will result in the DriveMod Forklift being widely available to under-served forklift automation applications that require 10k+ lb. load capacity and use non-standard pallets.

2024 Financial Review:

2024 revenue was $368 thousand compared to $1.5 million in 2023. 2024 revenue was derived primarily from EAS software subscriptions from DriveMod Stockchaser vehicle deployments whereas prior year revenue was primarily the result of NRE (“Non-Recurring Engineering”) contracts.

Total costs and expenses in 2024 were $23.2 million, a decrease of $1.6M or 6.5% from $24.8 million in 2023. This decrease was caused by a decrease of $686.6 thousand in cost of revenue, $1.5 million in R&D, offset by an increase of $507.9 thousand in G&A. The decrease in cost of revenue is driven by the lower costs associated with EAS revenue compared to the NRE contracts in 2023. The decrease in R&D expense was primarily driven by capitalizing costs for specific customers and capitalizing costs related to the development of software. The increase in G&A expenses is due to an increase in executive bonuses offset by  a decrease in personnel costs, reduced insurance premiums and spending improvements on general office expenses. Other income (expense), net were $(6.4) million compared to $534.7 thousand in 2023. The increase in expense was primarily driven by the fair value measurement of $5.4 million for the warrant liability.

Net loss for 2024 was $(29.3) million compared to $(22.8) million in 2023. For the year-end 2024 net loss per share was $(2,213), based on basic and diluted weighted average shares outstanding of approximately 13.2(1) thousand. This compares to a net loss per share of $(6,529) in 2023, based on approximately 3.5(1) thousand basic and diluted weighted average shares outstanding.

Q4 2024 Financial Review:

Fourth quarter revenue was $306.4 thousand compared to $40.4 thousand in the fourth quarter of 2023. Similar to prior year, fourth quarter 2024 revenue consisted of EAS software subscriptions from DriveMod Stockchaser vehicle deployments.

Total costs and expenses in the fourth quarter were $5.8 million, an increase of $400 thousand or 7.4% from $5.4 million in the fourth quarter of 2023. This increase was due to an increase of $149.2 thousand in cost of revenue due to additional EAS subscriptions in 2024 vs 2023, and an increase of $1.2 million in G&A primarily due to an increase in personnel costs. This is offset by a $912.6 thousand reduction in  R&D expenses, primarily driven by capitalizing costs for specific customers and capitalizing costs related to the development of software.  For the fourth quarter 2024, other income (expense), net was $(6.5) million compared to $38 thousand in the fourth quarter of 2023. The increase in expense was primarily driven by the fair value measurement of $5.4 million for the warrant liability.

Net loss for the fourth quarter was $(12.0) million compared to $(5.4) million in the corresponding quarter of 2023. Fourth quarter 2024 net loss per share was $(502), based on basic and diluted weighted average shares outstanding of approximately 24 thousand in the quarter. This compares to a net loss per share of $(1,376) in the fourth quarter of 2023, based on approximately 3.9 thousand basic and diluted weighted average shares outstanding.

(1)

All information has been retroactively adjusted to reflect the 1-for-100 reverse stock split effected on July 3, 2024 and the 1-for-150 reverse stock split effected on February 18, 2025.

Balance Sheet Highlights:

Cyngn’s unrestricted cash and short-term investments at the end of 2024 total $23.6 million compared to $3.6 million as of December 31, 2023.  At the end of the same period, working capital was $22.1 million and total stockholders’ equity was $11.6 million, as compared to year-end working capital of $7.4 million and total stockholders’ equity of $10.6 million, respectively as of December 31, 2023.  The Company had no debt as of December 31, 2024 and December 31, 2023 and to date, no one on the current management team has sold any shares of Company stock.

About Cyngn

Cyngn develops and deploys scalable, differentiated autonomous vehicle technology for industrial organizations. Cyngn’s self-driving solutions allow existing workforces to increase productivity and efficiency. The Company addresses significant challenges facing industrial organizations today, such as labor shortages, costly safety incidents, and increased consumer demand for eCommerce.

Cyngn’s DriveMod Kit can be installed on new industrial vehicles at end of line or via retrofit, empowering customers to seamlessly adopt self-driving technology into their operations without high upfront costs or the need to completely replace existing vehicle investments.

Cyngn’s flagship product, its Enterprise Autonomy Suite, includes DriveMod (autonomous vehicle system), Cyngn Insight (customer-facing suite of AV fleet management, teleoperation, and analytics tools), and Cyngn Evolve (internal toolkit that enables Cyngn to leverage data from the field for artificial intelligence, simulation, and modeling). For all terms referenced within, please refer to the Company’s annual report on Form 10-K with the SEC filed on March 7, 2024.

Where to find Cyngn:

Website: https://cyngn.comX: https://x.com/cyngnLinkedIn: https://www.linkedin.com/company/cyngnYouTube: https://www.youtube.com/@cyngnhq

Media Contact
Luke Renner
media@cyngn.com 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as “expects,” “anticipates,” “believes,” “will,” “will likely result,” “will continue,” “plans to,” “potential,” “promising,” and similar expressions. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described from time to time in the Company’s reports to the Securities and Exchange Commission (SEC), including, without limitation the risk factors discussed in the Company’s annual report on Form 10-K filed with the SEC on March 7, 2024. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Cyngn undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

CYNGN INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

Year Ended December 31,

2024

2023

Revenue

$

368,138

$

1,489,317

Costs and expenses

Cost of revenue

535,708

1,222,321

Research and development

11,259,641

12,719,983

General and administrative

11,400,864

10,892,955

Total costs and expenses

23,196,213

24,835,259

Loss from operations

(22,828,075)

(23,345,942)

Other income (expense), net

Interest income (expense), net

(1,117,546)

137,887

Change in fair value of warrant liability

(5,359,780)

Other income (expense), net

53,117

396,825

Total other income (expense), net

(6,424,209)

534,712

Net loss

$

(29,252,284)

$

(22,811,230)

Net loss per share attributable to common stockholders, basic and diluted

$

(2,212.56)

$

(6,528.92)

Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted(1)

13,221

3,494

(1)

All information has been retroactively adjusted to reflect the 1-for-100 reverse stock split effected on July 3, 2024 and the 1-for-150 reverse stock split effected on February 18, 2025.

 

CYNGN INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

December 31,

December 31,

2024

2023

ASSETS

CURRENT ASSETS

Cash

$

23,617,733

$

3,591,623

Short-term investments

4,561,928

Prepaid expenses and other current assets

1,965,222

1,316,426

TOTAL CURRENT ASSETS

25,582,955

9,469,977

NON-CURRENT ASSETS

Property and equipment, net

2,319,402

1,486,672

Right-of-use asset, net

297,918

992,292

Intangible assets, net

1,895,074

1,084,415

TOTAL NON-CURRENT ASSETS

4,512,394

3,563,379

TOTAL ASSETS

$

30,095,349

$

13,033,356

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES

Accounts payable

$

297,778

$

196,963

Accrued expenses and other current liabilities

2,874,216

1,201,142

Current operating lease liability

317,344

682,718

TOTAL CURRENT LIABILITIES

3,489,338

2,080,823

Warrant liability

15,012,361

Non-current operating lease liability

317,344

TOTAL LIABILITIES

18,501,699

2,398,167

Commitments and contingencies (Note 12)

STOCKHOLDERS’ EQUITY

Common stock, Par $0.00001; 200,000,000 shares authorized, 199,110(1) and 5,147(1) shares issued and outstanding as of December 31, 2024 and 2023, respectively

2

Additional paid-in capital(1)

200,863,551

170,652,808

Accumulated deficit

(189,269,903)

(160,017,619)

TOTAL STOCKHOLDERS’ EQUITY

11,593,650

10,635,189

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

$

30,095,349

$

13,033,356

(1)

All information has been retroactively adjusted to reflect the 1-for-100 reverse stock split effected on July 3, 2024 and the 1-for-150 reverse stock split effected on February 18, 2025.

 

CYNGN INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

Year Ended December 31,

2024

2023

CASH FLOWS FROM OPERATING ACTIVITIES

Net loss

$

(29,252,284)

$

(22,811,230)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

669,409

961,281

Stock-based compensation

2,449,191

3,208,103

Realized gain on short-term investments

(113,072)

(443,392)

Patent impairment

118,831

Change in fair value of warrant liability

5,359,780

Accretion of interest and amortization of debt issuance costs

1,177,174

Changes in operating assets and liabilities:

Prepaid expenses, operating lease right-of-use assets, and other current assets

(646,282)

(1,403,049)

Accounts payable

100,815

41,020

Accrued expenses, lease liabilities, and other current liabilities

10,642,938

969,662

Net cash used in operating activities

(9,493,500)

(19,477,605)

CASH FLOWS FROM INVESTING ACTIVITIES

Purchase of property and equipment

(1,051,481)

(1,045,822)

Acquisition of intangible asset

(954,229)

(718,711)

Disposal of assets

265,940

180,898

Purchase of short-term investments

(7,562,761)

(21,573,199)

Proceeds from maturity of short-term investments

12,237,761

29,519,000

Net cash provided by investing activities

2,935,230

6,362,166

CASH FLOWS FROM FINANCING ACTIVITIES

Proceeds from at-the-market equity financing, net of issuance costs

6,789,427

1,747,468

Proceeds from public issuance of common stock and pre-funded warrants and exercise of pre-funded warrants, net of offering costs

22,369,285

4,380,975

Proceeds from the Notes, net of issuance costs

1,801,265

Repayment of the Notes

(4,375,000)

Proceeds from exercise of stock options

8,528

Issuance costs for stock dividend and restricted stock units

(597)

(16,182)

Net cash provided by financing activities

26,584,380

6,120,789

Net increase (decrease) in cash and cash equivalents and restricted cash

20,026,110

(6,994,650)

Cash and cash equivalents and restricted cash, beginning of year

3,591,623

10,586,273

Cash and cash equivalents and restricted cash, end of year

$

23,617,733

3,591,623

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cyngn-reports-2024-fourth-quarter-and-year-end-financial-results-302393532.html

SOURCE Cyngn

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

HelloNation Article Highlights Sterile Compounding and Medication Safety With Insights From Compounding Pharmacist Expert Laura Temple

Published

on

By

The article explains how sterile compounded medications are prepared to reduce the risk of contamination and support safe, customized treatments.

AZLE, Texas, July 21, 2026 /PRNewswire/ — What does sterile compounding mean for medication safety? HelloNation has published an article explaining how sterile compounding helps pharmacies prepare highly specialized medications while adhering to strict contamination-prevention procedures.

The article features insights from Laura Temple, Compounding Pharmacist Expert and Owner of Laura’s Pharmacy in Azle, Texas. It explains that sterile compounding is a specialized process for preparing medications in carefully controlled environments designed to reduce the risk of contamination. Sterile compounded medications are often used for injections, eye drops, IV medications, and other therapies that require the highest levels of cleanliness and precision.

The HelloNation article explains that sterile compounded medications differ from commercially manufactured drugs because they are prepared individually for a patient’s unique medical needs. Physicians may prescribe compounded prescriptions when a patient requires a customized dosage, a combination medication, or a treatment not commercially available. Because these medications often bypass the body’s natural defenses, medication safety depends on strict preparation standards throughout the compounding process.

The article describes how pharmacies that provide sterile compounding rely on cleanroom environments equipped with filtered-air systems, specialized equipment, and contamination-prevention protocols. Pharmacists and technicians follow detailed gowning, sterilization, and handwashing procedures before handling medication ingredients. These measures are designed to support medication safety by limiting exposure to bacteria, particles, and other contaminants.

According to the article, environmental monitoring also plays a critical role in sterile compounding. Temperature control, air quality testing, and routine equipment inspections help maintain consistent preparation standards. The article notes that sterile compounded medications may undergo additional quality assurance checks before being dispensed to patients. These procedures help support both treatment effectiveness and patient safety.

The HelloNation article also explains that pharmacies performing sterile compounding are expected to follow USP guidelines established for sterile preparation. These USP guidelines outline requirements for cleanroom pharmacy operations, environmental testing, employee training, and quality assurance practices. The article emphasizes that maintaining compliance with USP guidelines helps reinforce contamination prevention and consistent preparation standards for compounded prescriptions.

Patients seeking sterile compounded medications may also look for pharmacies that participate in accreditation programs or are overseen by state boards. The article explains that these programs review safety procedures, documentation practices, and facility standards to help maintain medication safety. Regular environmental monitoring and staff competency evaluations are also identified as important safeguards in sterile compounding operations.

The article further explains that communication between pharmacists, healthcare providers, and patients remains an important part of safe compounded prescriptions. Compounding pharmacists review prescriptions carefully, confirm dosing instructions, and evaluate ingredient compatibility before preparation begins. This collaborative approach supports medication safety by reducing the risk of errors and ensuring treatments meet individual patient needs.

The article concludes that sterile compounding continues to play an important role in healthcare, particularly for patients requiring customized therapies that are unavailable through traditional manufacturing channels. Whether preparing IV medications, injectable therapies, or other sterile compounded medications, pharmacies rely on contamination prevention procedures and strict preparation standards to support patient care. The article notes that understanding how sterile compounding works can help patients feel more informed about the safety measures involved in preparing specialized medications.

What Sterile Compounding Means for Medication Safety features insights from Laura Temple, a compounding pharmacist expert at Laura’s Pharmacy in Azle, Texas, on HelloNation.

About HelloNation

HelloNation is America’s Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused publications and innovative “edvertising” approach, HelloNation delivers content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities.

View original content to download multimedia:https://www.prnewswire.com/news-releases/hellonation-article-highlights-sterile-compounding-and-medication-safety-with-insights-from-compounding-pharmacist-expert-laura-temple-302831275.html

SOURCE HelloNation

Continue Reading

Technology

CIOs Forced to Rethink Manual Compliance Processes as Regulatory Complexity Rises, Says Info-Tech Research Group

Published

on

By

Regulatory demands are increasing in volume, complexity, and speed, leaving many organizations reliant on fragmented, manual approaches that slow response times and increase risk. New insights from Info-Tech Research Group show that organizations need to adopt more structured and scalable approaches to keep pace with regulatory change. The firm’s recently published blueprint, Build a Regulatory IT Response Engine, provides frameworks, tools, and step-by-step guidance to help organizations translate regulatory requirements into actionable IT controls and prioritized initiatives.

ARLINGTON, Va., July 21, 2026 /PRNewswire/ — Growing regulatory pressure across jurisdictions is forcing organizations to rethink how they interpret, prioritize, and execute compliance requirements. Many IT teams continue to operate with inconsistent processes and limited coordination, resulting in delayed initiatives and increased exposure to financial and reputational risk. Info-Tech’s blueprint, Build a Regulatory IT Response Engine, introduces a coordinated and repeatable approach to help IT leaders operationalize compliance and improve execution outcomes.

Info-Tech’s findings indicate that while organizations recognize the need for faster and more consistent regulatory response, they continue to face barriers such as fragmented interpretation of requirements, weak prioritization, and limited scalability. AI-enabled tools can help streamline analysis and accelerate response planning, but without a coordinated approach grounded in governance and human oversight, those benefits are difficult to realize.

“Regulatory response is becoming too complex to manage through disconnected, manual processes,” says Ahmad Jowhar, senior research analyst at Info-Tech Research Group. “IT leaders need a repeatable way to interpret requirements, prioritize action, and use AI to accelerate planning without losing the governance and oversight needed to execute effectively.”

Key Challenges IT Leaders Face in Regulatory Response

Despite ongoing investments in compliance, organizations continue to face systemic challenges that hinder effective execution. Info-Tech’s blueprint highlights several areas where IT and compliance leaders struggle most:

Fragmented and manual processes that slow regulatory interpretation and response.Inconsistent application of regulatory requirements across teams and jurisdictions.Poor prioritization of IT initiatives, leading to missed deadlines and duplicated effort.Limited scalability to manage increasing regulatory volume and complexity.Misalignment between compliance activities and broader business priorities.

Info-Tech’s Framework for Building a Regulatory IT Response Engine

To address these challenges, Info-Tech recommends a structured, AI-enabled approach that improves consistency, speed, and scalability. The firm’s Build a Regulatory IT Response Engine blueprint outlines the following key priorities for IT leaders:

Define the regulatory landscape: Establish organizational context, governance structures, and a centralized inventory of applicable regulations.Translate requirements into IT controls: Use AI-enabled analysis and structured assessments to convert regulatory obligations into actionable controls.Prioritize IT initiatives: Align initiatives based on cost, effort, impact, and regulatory timelines to reduce execution risk.Build and communicate a roadmap: Develop a clear, resource-aligned roadmap to guide execution and stakeholder alignment.Establish a repeatable process: Continuously monitor, adapt, and refine regulatory response capabilities to maintain compliance over time.

Organizations that adopt this structured approach can move from reactive compliance efforts to a more proactive and scalable model that shortens response timelines, reduces manual effort, and strengthens execution.

The firm’s Build a Regulatory IT Response Engine blueprint includes practical tools such as a Regulation Inventory Tool, a Regulatory Response IT Action Plan Tool, a Communication Deck Template, and a Compliance Program Framework. By applying these resources, IT leaders can standardize regulatory responses, improve prioritization, and help ensure compliance initiatives are executed on time and in alignment with business priorities.

For exclusive and timely commentary from Info-Tech’s experts, including Ahmad Jowhar, and access to the complete Build a Regulatory IT Response Engine blueprint, please contact pr@infotech.com.

About Info-Tech Research Group

Info-Tech Research Group is the “get things done” partner for over 30,000 IT, HR, and marketing leaders worldwide. The fastest growing research and advisory firm, Info-Tech enables leaders to make well-informed decisions and transform their organizations through AI, strategic foresight, step-by-step methodologies, practical tools, industry-leading advisory, and training programs. For nearly 30 years, tens of thousands of private and public organizations have trusted Info-Tech to lead their most important initiatives through periods of change and deliver outcomes that truly matter.

To learn more about Info-Tech’s HR research and advisory services, visit McLean & Company, and for data-driven software buying insights and vendor evaluations, visit the firm’s SoftwareReviews platform.

Media professionals can register for unrestricted access to research across IT, HR, and software and hundreds of industry analysts through the firm’s Media Insiders program. To gain access, contact pr@infotech.com.

For information about Info-Tech Research Group or to access the latest research, visit infotech.com and connect via LinkedIn and X.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cios-forced-to-rethink-manual-compliance-processes-as-regulatory-complexity-rises-says-info-tech-research-group-302831286.html

SOURCE Info-Tech Research Group

Continue Reading

Technology

Atomera to Announce Second Quarter 2026 Financial Results and Host Webinar on Tuesday, August 4, 2026

Published

on

By

LOS GATOS, Calif., July 21, 2026 /PRNewswire/ — Atomera Incorporated (NASDAQ: ATOM), a semiconductor materials and technology licensing company, announced today that it plans to release its second quarter 2026 financial results after the market closes on Tuesday, Aug. 4, 2026.

The company will host a live video Zoom webinar at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on Tuesday, Aug. 4, 2026, to discuss the results. The live webinar can be accessed through Atomera’s investor relations website at https://ir.atomera.com. A replay of the webcast will be available for 12 months. To pre-register for the webinar, use the following link.

https://atomera.zoom.us/webinar/register/WN_OJFbTWe1SIyV69LLdDadCw

About Atomera

Atomera Incorporated is a semiconductor materials and technology licensing company focused on deploying its proprietary, silicon-proven technology into the semiconductor industry. Atomera has developed Mears Silicon Technology™ (MST®), which increases performance and power efficiency in semiconductor transistors. MST can be implemented using equipment already deployed in semiconductor manufacturing facilities and is complementary to other nano-scaling technologies already in the semiconductor industry roadmap.  More information can be found at www.atomera.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/atomera-to-announce-second-quarter-2026-financial-results-and-host-webinar-on-tuesday-august-4-2026-302830602.html

SOURCE Atomera Incorporated

Continue Reading

Trending